Groundbreaking cancer pill enters first human testing
NCT ID NCT05478486
Summary
This was the first human trial of a new oral medication called MSP008-22, designed to treat advanced solid tumors like breast, ovarian, and prostate cancer. The study tested single, increasing doses in 7 patients with stage IV cancer to check if the drug was safe and how the body processes it. The main goal was to find the highest dose patients could tolerate without severe side effects, providing safety data for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) of TATA Memorial Centre
Navi Mumbai, Maharashtra, 410210, India
Conditions
Explore the condition pages connected to this study.